Ribosome biogenesis in disease: new players and therapeutic targets.
Jiao L, Liu Y, Yu XY, Pan X, Zhang Y, Tu J, Song YH, Li Y. · 2023
Read Ribosome biogenesis in disease: new players and therapeutic targets. by Jiao L, Liu Y, Yu XY, Pan X, Zhang Y, Tu J, Song YH, Li Y. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9826790.txt.
Introduction
Jiao and co-authors review ribosome biogenesis in disease, naming new players and drug targets. Ribosomes are the cell's protein building machines. Making them drives growth, division, and cell change. Three signal systems jointly steer that production line.
The mTORC1 and Myc pathways lead the control set. Noncoding RNAs form the third steering arm. The review compares our ribosomes with bacterial ones. Human ribosomes carry four RNAs and 80 proteins. That contrast explains how antibiotics hit bacteria selectively. Resistance tricks bacteria use get their own survey. Frameshifting, stalling, and collision events are explained. Disease links range from blood ills to brain decline. Heart disease and cancer feature strongly in the tour. Trials and therapies aimed at ribosome making are summed up. Vaccine angles for COVID-19 close the disease survey.
Catalog record
| CREATOR | Jiao L, Liu Y, Yu XY, Pan X, Zhang Y, Tu J, Song YH, Li Y. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 135 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Ribosome biogenesis in disease: new players and therapeutic targets By Lijuan Jiao, Yuzhe Liu, Xi-Yong Yu, Xiangbin Pan, Yu Zhang, Junchu Tu, Yao-Hua Song, Yangxin Li Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-022-01285-4 ABSTRACT The ribosome is a multi-unit complex that translates mRNA into protein. Ribosome biogenesis is the process that generates ribosomes and plays an essential role in cell proliferation, differentiation, apoptosis, development, and transformation. The mTORC1, Myc, and noncoding RNA signaling pathways are the primary mediators that work jointly with RNA polymerases and ribosome proteins to control ribosome biogenesis and protein synthesis. Activation of mTORC1 is required for normal fetal growth and development and tissue regeneration after birth. Myc is implicated in cancer development by enhancing RNA Pol II activity, leading to uncontrolled cancer cell growth. The deregulation of noncoding RNAs such as microRNAs, long noncoding RNAs, and circular RNAs is involved in developing blood, neurodegenerative diseases, and atherosclerosis. We review the similarities and differences between eukaryotic and bacterial ribosomes and the molecular mechanism of ribosome-targeting antibiotics and bacterial resistance. We also review the most recent findings of ribosome dysfunction in COVID-19 and other conditions and discuss the consequences of ribosome frameshifting, ribosome-stalling, and ribosome-collision. We summarize the role of ribosome biogenesis in the development of various diseases. Furthermore, we review the current clinical trials, prospective vaccines for COVID-19, and therapies targeting ribosome biogenesis in cancer, cardiovascular disease, aging, and neurodegenerative disease. INTRODUCTION The primary function of the ribosome is to synthesize proteins with mRNA as a template and amino acids as raw materials.1 Studies have demonstrated that the ribosome affects the rate of protein synthesis and plays a role in cell proliferation, differentiation, apoptosis, and transformation.2–4 When the ribosome is abnormal, it can severely affect the cell fate, causing various ribosome-related diseases such as COVID-19 virus infection, bacterial resistance, cardiovascular diseases (CVD), blood diseases, neurodegenerative diseases, and cancer.5–7 This review focuses on ribosome abnormalities to explore the molecular mechanisms of common diseases. Along this line, we discussed how the ribosome biogenesis pathway could be targeted for therapeutic purposes. For example, ribosomal protein S6 kinase 1 (S6K1) and nucleolin (Ncl) are drug targets for the treatment of cardiac hypertrophy and myocardial infarction (MI). RIBOSOMES AND RIBOSOME BIOGENESIS Eukaryotic ribosome Ribosomes comprise four ribosomal RNAs (rRNAs) and 80 ribosomal proteins (RPs). The eukaryotic ribosome includes two subunits, the 40S small subunit, and the 60S large subunit, which combine to form the 80S ribosome with translational activity.8 The 40S subunit is responsible for recognizing and binding messenger RNA (mRNA), while the function of the 60S subunit is to form peptide bonds. Hence, the ribosome is known as the “protein synthesis factory.” Ribosome biogenesis is the process of assembling the ribosome complex.9 This highly coordinated process is closely associated with protein synthesis, cell proliferation, differentiation, and apoptosis.10 Specifically, the process demands the organized synthesis of four rRNAs, 80 RPs, and ~70 small nucleolar RNAs.11,12 Within the nucleolus, the 47S pre-rRNA is transcribed from rDNA and cleaved to yield the 18S, 5.8S, and 28S rRNA. After synthesis in the cytoplasm, the RPs are imported to the nucleus to join the rRNAs. After modifications by snoRNAs, the rRNAs exit from the nucleolus. The 60S ribosome subunit is formed when the 5.8S, 28S rRNA is joined by the 5S rRNA in the nucleus and exported to the cytoplasm, while the 40S ribosome subunit is formed from the 18S rRNA. In the nucleolus of eukaryote cells, rRNA, RPs, small nucleolar RNAs, and other closely-related proteins participate in the generation of ribosome precursor 60S (pre-60S) and precursor 40S (pre-40S). The final ribosome assembly and maturation are completed when these molecules are exported to the cytoplasm (Fig. 1a).13Fig. 1Schematic of ribosome biogenesis. a Eukaryotic ribosome biogenesis is a highly orchestrated process involving RNA Pol I, Pol II, and Pol III, which are responsible for transcribing rDNA to rRNA, producing 47S pre-rRNA in the nucleolus. The 4 rRNAs then assemble together with RPs to form a small ribosomal subunit (40S) and a large ribosomal subunit (60S). After assembly, the ribosome complex is exported from the nucleolus to the cytoplasm to form mature ribosomes for protein synthesis. b Bacterial ribosome biogenesis starts with the transcription of the precursors of 23S, 16S, and 5S rRNAs, and some tRNAs in the cytoplasm. The rRNAs then assemble with RPs to form a 30S small subunit and a 50S large subunit. After assembly, the ribosome complex forms mature ribosomes for protein synthesis. RP ribosome protein, RNA pol Ι/II/III RNA polymerase Ι/II/III, RNAP RNA polymerase, rDNA ribosomal DNA, rRNA, ribosomal RNA, tRNA transfer RNA The maturation needs a series of chemical modifications of precursor rRNAs (pre-rRNAs). RNA polymerase I (Pol I) is required to process pre-47S transcripts into 5.8S, 18S, and 28S rRNA, and RNA polymerase III (Pol III) is responsible for the transcription of 5S rRNA.13 RPs are assembled into pre-rRNA transcripts and accelerate the formation of mature rRNA.14,15 Some RPs have other functions besides making ribosomes, including replication of DNA and cell division.16,17 Of note, ribosome dysfunction can lead to cellular dysfunction and eventually induce various diseases. Bacteria ribosome Bacteria do not have a nucleus but have a cell wall, cell membrane, cytoplasm, and ribosomes. The bacterial ribosome is formed by the 30S, and 50S subunits, including three types of rRNA (23S, 16S, and 5S rRNA) and 54 RPs.18 Biogenesis of the bacterial ribosome starts when the primary rRNAs are transcribed, including 23S, 16S, and 5S rRNA precursors and some transfer RNAs (tRNAs).19 This process requires the participation of RNA polymerase (RNAP), a multi-subunit enzyme that synthesizes all types of RNA and catalyzes the transcription process of rDNA.20 Precursors of rRNAs and tRNAs fold into a unique structure, then excised from their primary transcripts. The 16S rRNA then assembles with RPs to form a 30S small subunit, while the 23S and 5S rRNAs assemble to form a 50S large subunit. The bacterial ribosomes are synthesized in the cytoplasm. After assembly, the ribosome complex forms the 70S mature ribosome rather than 80S due to tertiary structure (Fig. 1b). Ribosome biogenesis is the process of creating ribosomes in a highly regulated manner. This process involves the synthesis of rRNAs and many RPs, which are required for proliferation and cell division. SIGNALING PATHWAYS INVOLVED IN RIBOSOME BIOGENESIS Ribosome biogenesis is regulated by several signaling pathways, among which mammalian targets of rapamycin (mTOR), myelocytomatosis oncogene (Myc), and noncoding RNA (ncRNA) are the most important regulators. mTOR mTOR is a serine/threonine kinase that regulates ribosome biogenesis. mTOR is assembled into multiple complexes, such as mTOR complex 1/2 (mTORC1/2).21 mTORC1 senses environmental cues to promote cellular anabolism and inhibit catabolism. The mTORC1 pathway regulates pre-rRNA transcription, rRNA synthesis, and RP expression. mTORC1 positively regulates rDNA transcription by activating S6K1 and promotes the synthesis of ribosomal 40S subunits through RPS6. mTORC1 promotes the initiation and elongation of mRNA through eIF4E and eIF2α. mTORC1 also induces translation initiation by inactivating 4E-BPs. The RP assembly factor Urb1 is a downstream target of mTORC1 signaling. mTORC1 promotes the translation of mRNA by inhibiting the binding of LARP1 and PABPC1 (Fig. 2).22Fig. 2mTORC1 and ribosome biogenesis. Through phosphorylation, mTORC1 activates S6K1, which enhances rDNA transcription. mTORC1phosphorylates RPS6 to promote the synthesis